The Enhanced Liver Fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values

被引:230
作者
Lichtinghagen, Ralf [1 ]
Pietsch, Daniel [1 ]
Bantel, Heike [2 ]
Manns, Michael P. [2 ]
Brand, Korbinian [1 ]
Bahr, Matthias J. [2 ,3 ]
机构
[1] Hannover Med Sch, Inst Clin Chem, D-30623 Hannover, Germany
[2] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30623 Hannover, Germany
[3] Sana Kliniken Lubeck, Dept Med 1, Lubeck, Germany
关键词
ELF score; TIMP; Hyaluronic acid; Hyaluronate; PIIINP; Liver fibrosis; Cirrhosis; CHRONIC HEPATITIS-C; NONINVASIVE MARKERS; CLINICAL-OUTCOMES; SERUM MARKERS; CIRRHOSIS; PREDICTION; DISEASE;
D O I
10.1016/j.jhep.2013.03.016
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background 82 Aims: Progressive fibrosis is a major cause of morbidity and mortality in chronic liver disease. To replace liver biopsy for disease staging, multiple serum markers are under evaluation with multiparametric panels yielding the most promising results. The Enhanced Liver Fibrosis (ELF) score is an ECM marker set consisting of tissue inhibitor of metalloproteinases 1 (TIMP-1), amino-terminal propeptide of type III procollagen (PIIINP) and hyaluronic acid (HA) showing good correlations with fibrosis stages in chronic liver disease. Methods: The ELF score was measured in 400 healthy controls and 79 chronic hepatitis C patients using an AD VIA Centaur automated system. The ELF score was calculated using the published algorithm combining TIMP-1, PIIINP and HA values. Patients' fibrosis stage was defined histologically. ROC analyses were performed to study marker validity. Reference values and influence factors for the ELF score were validated. Results: ELF score reference values ranged from 6.7 to 9.8 and were significantly higher for men vs. women (7.0-9.9 vs. 6.6-9.3, respectively). Afternoon values were slightly higher than morning values (6.7-9.9 vs. 6.6-9.5, respectively). Age was a notable influence factor. We identified three cut-off values: 7.7 for a high sensitivity exclusion of fibrosis, 9.8 for a high specificity identification of fibrosis (sensitivity 69%, specificity 98% for moderate fibrosis), and 11.3 to discriminate cirrhosis (sensitivity 83%, specificity 97%). ELF score validity was superior to the results of the single tests. Conclusions: The ELF score can predict moderate fibrosis and cirrhosis. However, influence factors such as gender and age need to be taken into account. (C) 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:236 / 242
页数:7
相关论文
共 29 条
  • [11] Pathogenesis of Liver Fibrosis
    Hernandez-Gea, Virginia
    Friedman, Scott L.
    [J]. ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6, 2011, 6 : 425 - 456
  • [12] Hoffmann G, 2011, FORSCHUNGSBERICHT IT, V42, P124
  • [13] Horn PS., 2005, Reference Intervals, A User's Guide
  • [14] Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study
    Imbert-Bismut, F
    Ratziu, V
    Pieroni, L
    Charlotte, F
    Benhamou, Y
    Poynard, T
    [J]. LANCET, 2001, 357 (9262) : 1069 - 1075
  • [15] HISTOLOGICAL GRADING AND STAGING OF CHRONIC HEPATITIS
    ISHAK, K
    BAPTISTA, A
    BIANCHI, L
    CALLEA, F
    DEGROOTE, J
    GUDAT, F
    DENK, H
    DESMET, V
    KORB, G
    MACSWEEN, RNM
    PHILLIPS, MJ
    PORTMANN, BG
    POULSEN, H
    SCHEUER, PJ
    SCHMID, M
    THALER, H
    [J]. JOURNAL OF HEPATOLOGY, 1995, 22 (06): : 696 - 699
  • [16] FORMULATION AND APPLICATION OF A NUMERICAL SCORING SYSTEM FOR ASSESSING HISTOLOGICAL ACTIVITY IN ASYMPTOMATIC CHRONIC ACTIVE HEPATITIS
    KNODELL, RG
    ISHAK, KG
    BLACK, WC
    CHEN, TS
    CRAIG, R
    KAPLOWITZ, N
    KIERNAN, TW
    WOLLMAN, J
    [J]. HEPATOLOGY, 1981, 1 (05) : 431 - 435
  • [17] Noninvasive diagnosis of fibrosis in chronic liver disease
    Lichtinghagen, R
    Bahr, MJ
    [J]. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2004, 4 (05) : 715 - 726
  • [18] Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C
    Martinez, S. M.
    Fernandez-Varo, G.
    Gonzalez, P.
    Sampson, E.
    Bruguera, M.
    Navasa, M.
    Jimenez, W.
    Sanchez-Tapias, J. M.
    Forns, X.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (01) : 138 - 148
  • [19] Prediction of Clinical Outcomes in Primary Biliary Cirrhosis by Serum Enhanced Liver Fibrosis Assay
    Mayo, Marlyn J.
    Parkes, Julie
    Adams-Huet, Beverley
    Combes, Burton
    Mills, A. S.
    Markin, Rodney S.
    Rubin, Raphael
    Wheeler, Donald
    Contos, Melissa
    West, A. B.
    Saldana, Sandra
    Getachew, Yoflas
    Butsch, Robert
    Luketic, Velimir
    Peters, Marion
    Di Bisceglie, Adrian
    Bass, Nathan
    Lake, John
    Boyer, Thomas
    Martinez, Enrique
    Boyer, James
    Garcia-Tsao, Guadalupe
    Barnes, David
    Rosenberg, William M.
    [J]. HEPATOLOGY, 2008, 48 (05) : 1549 - 1557
  • [20] Noninvasive Assessment of Liver Fibrosis
    Nguyen, Doris
    Talwalkar, Jayant A.
    [J]. HEPATOLOGY, 2011, 53 (06) : 2107 - 2110